Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | SOD1 | P00441 | 1/20 | 0.46 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439660 | 0.87 | PARP10 (0.58) | PARP10GSTP1HDAC8FFAR1NPC1 | |
| SCHEMBL12885558 | 0.86 | MAOB (0.56) | PARP10RXRARXRBGSTP1TDP1 | |
| SCHEMBL10017577 | 0.85 | RXRA (0.47) | PARP10RXRARXRBSOD1GSTP1 | |
| SCHEMBL18027651 | 0.84 | GSTP1 (0.57) | PARP10GSTP1L3MBTL1FFAR1RAB9A | |
| SCHEMBL13929692 | 0.80 | MAOB (0.61) | PARP10RXRARXRBSOD1TDP1 | |
| SCHEMBL15336496 | 0.80 | MAOB (0.61) | PARP10RXRARXRBSOD1TDP1 | |
| SCHEMBL13462732 | 0.79 | GSTP1 (0.63) | RXRARXRBGSTP1L3MBTL1FFAR1 | |
| SCHEMBL12806827 | 0.79 | RXRA (0.60) | RXRARXRBGSTP1L3MBTL1FFAR1 | |
| SCHEMBL5370546 | 0.78 | PARP10 (0.65) | PARP10HDAC8TDP1L3MBTL1RAB9A | |
| SCHEMBL6734353 | 0.78 | PARP10 (0.47) | PARP10RXRARXRBHDAC8TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011772-B2 | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display device | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-9976086-B2 | Liquid crystal aligning agent containing polyimide precursor having thermally-leaving group and/or polyimide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20160264867-A1 | LIQUID CRYSTAL ALIGNING AGENT CONTAINING POLYIMIDE PRECURSOR HAVING THERMALLY-LEAVING GROUP AND/OR POLYIMIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20160244673-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-8901353-B2 | Polyimide precursor, polyimide, and liquid crystal aligning agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20120088888-A1 | POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088888-A1 | POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT | PUF60, F13A1, F12 | PARP10 1143/4885RXRA 2493/4885RXRB 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.